US continuous glucose monitor developer Dexcom has completed construction of its first manufacturing facility outside the United States, located in Athenry, Co. Galway, following a $325 million (€299.7m) investment. Drug Delivery Business reported on the milestone, confirmed on 31 March 2026.

Irish construction firm John Paul Construction announced the completion of the Dexcom Medical Devices Facility, concluding a 25-month programme to build the state-of-the-art manufacturing and office development.

The facility includes a highly technical production environment with cleanrooms, supporting laboratory and engineering spaces, and a four-storey office building. Once operational, it will develop and manufacture Dexcom's real-time CGMs, led by the latest-generation G7.

Dexcom broke ground on the facility in January 2024, after announcing plans to invest $325 million (€299.7m) in Athenry in May 2023. The investment was described by the company as one of the biggest single private sector investments ever made in the West of Ireland, with the potential to bring more than 1,000 jobs to the area.

John Paul Construction said in its announcement: "Dexcom has been a valued client throughout, and we appreciate the trust placed in us to deliver this significant investment. We would like to thank the design team, our project partners and the wider site team for their commitment and professionalism in bringing this project to completion."

The Athenry facility marks a significant expansion of Dexcom's global manufacturing footprint as demand for continuous glucose monitoring technology continues to grow across international markets.

Read the full story on the completion of Dexcom's Athenry manufacturing facility here.